Mucosal Damage and Neutropenia Are Required for Candida albicans Dissemination

Candida albicans fungemia in cancer patients is thought to develop from initial gastrointestinal (GI) colonization with subsequent translocation into the bloodstream after administration of chemotherapy. It is unclear what components of the innate immune system are necessary for preventing C. albicans dissemination from the GI tract, but we have hypothesized that both neutropenia and GI mucosal damage are critical for allowing widespread invasive C. albicans disease. We investigated these parameters in a mouse model of C. albicans GI colonization that led to systemic spread after administration of immunosuppression and mucosal damage. After depleting resident GI intestinal flora with antibiotic treatment and achieving stable GI colonization levels of C. albicans, it was determined that systemic chemotherapy with cyclophosphamide led to 100% mortality, whereas selective neutrophil depletion, macrophage depletion, lymphopenia or GI mucosal disruption alone resulted in no mortality. Selective neutrophil depletion combined with GI mucosal disruption led to disseminated fungal infection and 100% mortality ensued. GI translocation and dissemination by C. albicans was also dependent on the organism's ability to transform from the yeast to the hyphal form. This mouse model of GI colonization and fungemia is useful for studying factors of innate host immunity needed to prevent invasive C. albicans disease as well as identifying virulence factors that are necessary for fungal GI colonization and dissemination. The model may also prove valuable for evaluating therapies to control C. albicans infections.

[1]  E. Balish,et al.  The role of activated macrophages in resistance to experimental renal candidiasis. , 1977, Journal of the Reticuloendothelial Society.

[2]  K. Wilhelmus,et al.  Corneal virulence of Candida albicans strains deficient in Tup1-regulated genes. , 2007, Investigative ophthalmology & visual science.

[3]  E. Anaissie,et al.  A model of sustained gastrointestinal colonization by Candida albicans in healthy adult mice , 1990, Infection and immunity.

[4]  N. Kartsonis,et al.  Invasive candidiasis in cancer patients: observations from a randomized clinical trial. , 2005, Journal of Infection.

[5]  D. Stevens,et al.  Development of an Orogastrointestinal Mucosal Model of Candidiasis with Dissemination to Visceral Organs , 2006, Antimicrobial Agents and Chemotherapy.

[6]  G. Cole,et al.  Gastrointestinal and systemic candidosis in immunocompromised mice. , 1989, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[7]  H. Cooper,et al.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[8]  Stephen M. Wiesner,et al.  Gastrointestinal Colonization by Candida albicans Mutant Strains in Antibiotic-Treated Mice , 2001, Clinical Diagnostic Laboratory Immunology.

[9]  D. Irwin,et al.  Isogenic strain construction and gene mapping in Candida albicans. , 1993, Genetics.

[10]  N. Narita,et al.  Translocation model of Candida albicans in DBA-2/J mice with protein calorie malnutrition mimics hematogenous candidiasis in humans. , 2003, Microbial pathogenesis.

[11]  R. Sawyer,et al.  Effect of lectins on hepatic clearance and killing of Candida albicans by the isolated perfused mouse liver , 1992, Infection and immunity.

[12]  G. Fink,et al.  Nonfilamentous C. albicans Mutants Are Avirulent , 1997, Cell.

[13]  J. Papadimitriou,et al.  Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice. , 2003, Microbial pathogenesis.

[14]  J. Barnes,et al.  Host-parasite interactions in the pathogenesis of experimental renal candidiasis. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[15]  D. Schofield,et al.  Candida glabrata and Candida albicans; dissimilar tissue tropism and infectivity in a gnotobiotic model of mucosal candidiasis. , 2007, FEMS immunology and medical microbiology.

[16]  N. Rooijen,et al.  Human Malaria in Immunocompromised Mice An in Vivo Model to Study Defense Mechanisms against Plasmodium falciparum , 2000 .

[17]  M. Jutila,et al.  Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. , 1994, Journal of immunology.

[18]  M. Whiteway,et al.  Signaling through adenylyl cyclase is essential for hyphal growth and virulence in the pathogenic fungus Candida albicans. , 2001, Molecular biology of the cell.

[19]  J. Cutler,et al.  Effect of mouse phagocytes on Candida albicans in in vivo chambers , 1981, Infection and immunity.

[20]  M. Phaneuf,et al.  Gastrointestinal colonization and systemic dissemination by Candida albicans and Candida tropicalis in intact and immunocompromised mice , 1992, Infection and immunity.

[21]  A. Johnson,et al.  Control of filament formation in Candida albicans by the transcriptional repressor TUP1. , 1997, Science.

[22]  R. Berg Bacterial translocation from the gastrointestinal tract. , 1990, Trends in microbiology.

[23]  N. Van Rooijen,et al.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. , 1994, Journal of immunological methods.

[24]  D. Hess,et al.  Comparative virulence of Candida albicans yeast and filamentous forms in orally and intravenously inoculated mice , 2003, Critical care medicine.

[25]  E. Balish,et al.  Systemic candidosis in silica-treated athymic and euthymic mice , 1983, Infection and immunity.

[26]  R. Simmons,et al.  Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria , 1987, Infection and immunity.

[27]  P. Pizzo,et al.  Principles and Practice of Pediatric Oncology , 1989 .

[28]  J. Berman,et al.  Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1. , 1998, Science.

[29]  J. Lyczak,et al.  Salmonella enterica Serovar Typhi Modulates Cell Surface Expression of Its Receptor, the Cystic Fibrosis Transmembrane Conductance Regulator, on the Intestinal Epithelium , 2002, Infection and Immunity.

[30]  Shane Gillespie,et al.  Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  J. F. Brown,et al.  Administration of antigranulocyte monoclonal antibody RB6-8C5 prevents expression of acquired resistance to Listeria monocytogenes infection in previously immunized mice , 1994, Infection and immunity.

[32]  R. Sawyer Experimental pulmonary candidiasis , 1990, Mycopathologia.

[33]  P. Puccetti,et al.  Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice , 1989, Infection and immunity.

[34]  J. Beney,et al.  The direct cost and incidence of systemic fungal infections. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[35]  Yee-Chun Chen,et al.  Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway , 2002, Molecular microbiology.

[36]  E. Anaissie,et al.  Revisiting the source of candidemia: skin or gut? , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  J. Papadimitriou,et al.  Neutrophil depletion increases susceptibility to systemic and vaginal candidiasis in mice, and reveals differences between brain and kidney in mechanisms of host resistance. , 1996, Microbiology.

[38]  K. Engels,et al.  Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. , 2010, The Journal of infection.

[39]  M. Okudaira,et al.  Fungal infections in cancer patients: An international autopsy survey , 1992, European Journal of Clinical Microbiology and Infectious Diseases.

[40]  Sungching C Glenn,et al.  Invasive Fungal Infections in Pediatric Oncology Patients: 11-Year Experience at a Single Institution , 2005, Journal of pediatric hematology/oncology.

[41]  C. Nombela,et al.  Analysis of the serologic response to systemic Candida albicans infection in a murine model , 2001, Proteomics.

[42]  J. Hughes,et al.  A prospective study of septicaemia on a paediatric oncology unit: a three-year experience at The Royal Liverpool Children's Hospital, Alder Hey, UK. , 2005, European journal of cancer.

[43]  S. Cryz,et al.  Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model , 1983, Infection and immunity.

[44]  R. Johnston,et al.  Mechanisms of host defense against Candida species. I. Phagocytosis by monocytes and monocyte-derived macrophages. , 1991, Journal of immunology.

[45]  S. Shoham,et al.  The immune response to fungal infections , 2005, British journal of haematology.

[46]  J. Papadimitriou,et al.  The pathogenesis of acute systemic candidiasis in a susceptible inbred mouse strain , 1986, The Journal of pathology.

[47]  N. Marina,et al.  Candida tropicalis infections in children with leukemia. , 1993, Leukemia & lymphoma.

[48]  J. Sundberg,et al.  Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[49]  M. Marquis,et al.  CD8+ T Cells but Not Polymorphonuclear Leukocytes Are Required To Limit Chronic Oral Carriage of Candida albicans in Transgenic Mice Expressing Human Immunodeficiency Virus Type 1 , 2006, Infection and Immunity.

[50]  E. Coligan Current protocols in immunology , 1991 .

[51]  A. Kim,et al.  Hypoxia and Extraintestinal Dissemination of Candida Albicans Yeast Forms , 2002, Shock.

[52]  G. Pier,et al.  Virulence of Pseudomonas aeruginosa in a Murine Model of Gastrointestinal Colonization and Dissemination in Neutropenia , 2005, Infection and Immunity.

[53]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[54]  Stefan Bentink,et al.  Role of Calcineurin in Stress Resistance, Morphogenesis, and Virulence of a Candida albicans Wild-Type Strain , 2006, Infection and Immunity.

[55]  A. Baghian,et al.  Role of Activated Macrophages in Resistance to Systemic Candidosis , 1988, Journal of leukocyte biology.

[56]  H. Richet,et al.  Risk factors for candidemia in patients with acute lymphocytic leukemia. , 1991, Reviews of infectious diseases.

[57]  U. Kuruganti,et al.  In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon , 1989, Infection and immunity.

[58]  J. Regadera,et al.  Sustained gastrointestinal colonization and systemic dissemination by Candida albicans, Candida tropicalis and Candida parapsilosis in adult mice. , 2000, Diagnostic microbiology and infectious disease.

[59]  M. Whiteway,et al.  Candida albicans Killing by RAW 264.7 Mouse Macrophage Cells: Effects of Candida Genotype, Infection Ratios, and Gamma Interferon Treatment , 2002, Infection and Immunity.

[60]  W. Nedel,et al.  Risk factors and outcome for nosocomial breakthrough candidaemia. , 2006, The Journal of infection.

[61]  P. Puccetti,et al.  Evidence for macrophage-mediated protection against lethal Candida albicans infection , 1986, Infection and immunity.

[62]  H. Redmond,et al.  Macrophage-dependent candidacidal mechanisms in the murine system. Comparison of murine Kupffer cell and peritoneal macrophage candidacidal mechanisms. , 1993, Journal of immunology.